Friday December 4th: 7:00 – 9:00 pm
Is finerenone the answer for all our patients with diabetic kidney disease (DKD), is FIDELIO the last trial we need in DKD? Maybe not, but where does this trial fit in? Hot on the heels of the 4 pm session, “Understanding and Interpreting the Results of Mineralocorticoid Receptor Antagonists (MRA) Trials in Diabetic Kidney Disease (DKD)”, is a session by experts who can help put the results of the FIDELIO trial into context with what is already known about DKD. Not the least of which is insight from the trial’s principal investigator, Dr. George Bakris from the University of Chicago, USA.
This session is being chaired by Dr. Bertram Pitt, and Gerasimos Filippatos. Dr. Bertram Pitt, a Prof. of medicine emeritus at the University of Michigan in Ann Arbor, USA, is well known to long time CVCT attendees. An active CV trialists, he is a chair of man of NHLBI TOPCAT, Emphasis-HF, Break- DHF, STOP-CKD, Exceed, and Escape trials. Dr Gerasimos Filippatos from the University of Athens, GR is past President of the Heart Failure Association of the ESC, and has served on ESC and ACC/AHA Guidelines Committees.
Join this session for a more in depth look at DKD past, present, and future. What is a non-steroidal mineralocorticoid receptor antagonist (MRA), and how are they different from steroidal MRAs? Where does FIDELIO-DKD fit with other non-steroidal MRA cardiovascular and renal outcome trials or with other diabetes cardiorenal outcome trials? What else will FIGARO tell us? Finally, do MRAs have a place in heart failure with preserved ejection fraction (HfpEF)?
Additional speakers include Michel Azizi (Paris, FRA), Patrick Rossignol (Nancy, FRA), Rajiv Agarwal (Indianapolis, USA), and our esteemed course director, Faiez Zannad (Nancy, FRA). Stay tuned after the presentations for the moderated multi-stakeholder expert panel debate, where CV trialists, industry, and regulatory experts will answer questions and debate the future of MRA cardiorenal trials and therapy.